Discovery of 1,6-naphthyridines as a novel class of potent and selective human cytomegalovirus inhibitors [4]

Journal of Medicinal Chemistry

Volumn 42, Issue 16, 1999, Pages 3023-3025

  Chan, Laval ^a   Jin, Haolun ^a   Stefanac, Tomislav ^a   Lavallée, Jean François ^a   Falardeau, Guy ^a   Wang, Wei ^a   Bédard, Jean ^a   May, Suzanne ^a   Yuen, Leonard ^a  

^a Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 NAPHTHYRIDIN 5 ONE DERIVATIVE; 1,6 NAPHTHYRIDINE DERIVATIVE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LETTER;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; NAPHTHYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033549867     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902483     Document Type: Letter

References (18)

1. For recent reviews, see: (a) de Jong, M. D.; Galasso, G. J.; Gazzard, B.; Griffiths, P. D.; Jabs, D. A.; Kern, A. R.; Spector, S. A. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res. 1898, 39, 141-162.
2. (b) de Jong, M. D.; Boucher, C. A. B.; Danner, S. A.; Gazzard, B.; Griffiths, P. D.; Katlama, C.; Lange, J. M. A.; Richman, D. D.; Vella, S. Summary of the International Symposium on management of HIV, CMV and Hepatitis Virus Infections. Antiviral Res. 1998, 37, 1-16.
3. Hitchcock, M. J. M.; Jaffe, H. S.; Martin, J. C.; Stagg, R. J. Cidofovir, a New Agent with Potent Anti-Herpes Activity. Antiviral Chem. Chemother. 1996, 7 (3), 115-127.
4. (b) Noble, S.; Faulds, D. Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients. Drugs 1998, 56, 115-146.
5. (c) Perry, C. M.; Balfour, J. A. B. Formivirsen. Drugs 1999, 57, 375-380.
6. Balzarini, J.; Naesens, L.; De Clercq, E. New Antivirals-Mechanism of Action and Resistance. Curr. Opin. Microbiol. 1998, 1, 535-546.
7. (b) Erice, A. Resistance of Human Cytomegalovirus to Antiviral Drugs. Clin. Microbiol. Rev. 1999, 12, 286-297.
8. Peakdale Fine Chemicals Ltd., Glossop Derbyshire, U.K.
9. Carboxylic acid 4 is also available from Peakdale Fine Chemicals; however, in-house preparation was more economical.
10. Venuti, M. C.; Stephenson, R. A.; Alvarez, R.; Bruno, J. J.; Strosberg, A. M. Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazo[2,1-b]quinazoline. J. Med. Chem. 1988, 31, 2136-2145.
11. 2, Pd/C) to the benzylamine.
12. The regioselectivity of the 8-bromo derivative 8 was deduced by comparison of coupling constants with those of related compounds. Further confirmation was obtained from an X-ray crystal structure of 11.
13. Stille, J. K.; Groh, B. L. Stereospecific Cross-coupling of Vinyl Halides with Vinyl Tin Reagents Catalyzed by Palladium. J. Am. Chem. Soc. 1987, 109, 813-820.
14. 50.
15. (a) Bédard, J.; et al. Unpublished results. Full details of mechanistic studies as well as activity against HCMV strains susceptible or resistant to a panel of known inhibitors will be disclosed in a forthcoming publication,
16. (b) Bédard, J.; May, S.; Lis, M.; Tryphonas, L.; Drach, J.; Huffman, J.; Sidwell, R.; Chan, L.; Bowlin, T.; Rando, R. Comparative Study of the Anti-Human Cytomegalovirus Activities and toxicities of a Tetrahydrofuran Phosphonate Analogue of Guanosine and Cidofovir. Antimicrob. Agents Chemother. 1999, 43, 557-567 and references therein.
17. A novel class of HCMV inhibitors which does not inhibit DNA polymerase and is believed to interfere with an early event of the life cycle of the virus was recently disclosed, (a) Nemecek, C.; Andrei, G.; Bacqué, E.; Bashiardes, G.; Bousseau, A.; De Clercq, E.; Roy, C.; Snoeck, R. RPR CMV423: A New Chemical Family as Potent in vitro Inhibitors of Human Cytomegalovirus: Synthesis, Structure Activity Relationships and Biological Data. Abstract #93, presented at the Twelfth International Conference on Antiviral Research, Jerusalem, Israel, March 21-25, 1999; Antiviral Res. 1999, 41 (2).
18. (b) Andrei, G.; Bugnicourt, R. A.; Snoeck, R.; Decelle, T.; Nemecek, C.; De Clercq, E.; Roy, C. RPR11123, A Novel Inhibitor of HCMV Replication is Orally Bioavailable and Biologically Active in Body Fluids. Abstract #108, ibid.